Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ibuprofen + chlorphenamine maleate is a fixed-dose combination small-molecule drug used for the symptomatic relief of the common cold, influenza, and upper respiratory tract infections. It combines ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID) that reversibly inhibits cyclooxygenase enzymes (COX-1 and COX-2) to reduce pain, fever, and inflammation, with chlorphenamine maleate (chlorpheniramine maleate), a first-generation H1 histamine receptor antagonist that relieves symptoms such as runny nose, sneezing, and watery eyes. This combination is marketed under brand names such as Niofen Cold HBP and has been utilized as an active control in clinical trials evaluating natural plant extracts for the common cold.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ibuprofen + chlorphenamine maleate.